Compare CLNN & BWG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLNN | BWG |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6M | 143.1M |
| IPO Year | N/A | N/A |
| Metric | CLNN | BWG |
|---|---|---|
| Price | $3.98 | $8.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $32.67 | N/A |
| AVG Volume (30 Days) | ★ 124.8K | 53.8K |
| Earning Date | 03-23-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.37% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $214,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $82.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.28 | $6.86 |
| 52 Week High | $13.50 | $8.65 |
| Indicator | CLNN | BWG |
|---|---|---|
| Relative Strength Index (RSI) | 31.85 | 50.97 |
| Support Level | $3.88 | $8.47 |
| Resistance Level | $4.50 | $8.63 |
| Average True Range (ATR) | 0.42 | 0.09 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 5.16 | 42.86 |
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
BrandywineGLOBAL - Global Income Opportunities Fund Inc is a non-diversified, closed-end management investment company. The primary investment objective is to provide current income. The secondary investment objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing, under normal market conditions, at least 80% of its assets in world-wide fixed-income securities.